BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,700+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market an internally discovered product in the United States, BRUKINSA® (zanubrutinib)..
Featured Content
Saturday 2/20/21
Talk face to face with BeiGene »
Sunday 2/21/21
Talk face to face with BeiGene »
